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Coronavirus disease 2019 (COVID-19) was initially characterized due to its impacts on the respiratory system;
however, many recent studies have indicated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
significantly affects the brain. COVID-19 can cause neurological complications, probably caused by the induction
of a cytokine storm, since there is no evidence of neurotropism by SARS-CoV-2. In line with this, the COVID-19
outbreak could accelerate the progression or affect the clinical outcomes of neuropsychiatric conditions. Thus, we
analyzed differential gene expression datasets for clinical samples of COVID-19 patients and identified 171 genes
that are associated with the pathophysiology of the following neuropsychiatric disorders: alcohol dependence,
autism, bipolar disorder, depression, panic disorder, schizophrenia, and sleep disorder. Several of the genes
identified are associated with causing some of these conditions (classified as elite genes). Among these elite genes,
9 were found for schizophrenia, 6 for autism, 3 for depression/major depressive disorder, and 2 for alcohol
dependence. The patients with the neuropsychiatric conditions associated with the genes identified may require
special attention as COVID-19 can deteriorate or accelerate neurochemical dysfunctions, thereby aggravating
clinical outcomes.1. Introduction
Coronavirus disease 2019 (COVID-19) outbreak is a conundrum for
physicians and researchers alike, as it affects several tissues in addition to
the lungs, such as the cardiovascular system, kidneys, gut and brain
(Wadman, 2020; Wang et al., 2020; Zubair et al., 2020). Patients may
present ophthalmological and neurological manifestations including
conjunctivitis, confusion, seizure, stroke, and Guillain-Barre syndrome,
which may be associated with inflammation. Moreover, there is a close
relationship between the periphery of the body and the central nervous
system (CNS), where respiratory, cardiac, hepatic, renal and gastroin-
testinal symptoms can markedly affect the brain, via an event that has
been well characterized in patients with COVID-19, the cytokine storm.
The cytokine storm is an overreaction of immune system; cytokines areímica, Instituto de Ciências Basic
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production can lead to switching from having a protective role to a
harmful effect, resulting in attacks on healthy tissues, including the brain.
Although the CNS presents functional barriers, such as the blood-brain
barrier (BBB), after the severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection, the permeability of this barrier can be affected
as a consequence of the increased production, release and migration of
cytokines into the CNS. This, in turn, may trigger specific inflammatory
mechanisms that induce BBB breakdown and, consequently, brain
damage (Alam et al., 2020; Li et al., 2020; Yachou et al., 2020; Zubair
et al., 2020). Importantly, several neuropsychiatric and psychological
symptoms have been reported after SARS-CoV-2 infection (Troyer et al.,
2020; Wu et al., 2020). Thus, the COVID-19 outbreak could accelerate
the progression or affect the clinical outcomes of these conditions.as da Saúde Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos,
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during COVID-19 infection, with different outcomes (Paterson et al.,
2020; Troyer et al., 2020; Wu et al., 2020). We, herein, identified several
molecular markers associated with the pathophysiology of neuropsy-
chiatric disorders that were found to be differentially expressed in clin-
ical samples from patients with COVID-19. To the best of our knowledge,
this is the first report presenting a molecular link between neuropsy-
chiatric disorders and SARS-CoV-2 infection through the identification of




Clinical evidences are pointing to a correlation between COVID-19
and neurological conditions. Accordingly, we performed the search forFig. 1. Interaction network of genes associated with selected neuropsychiatric disorde
COVID-19. The interaction network was built in Cytoscape v.3.8.0, using the differen
the MalaCards Human Disease Database (https://www.malacards.org). Genes are re
yellow edges represent elite genes, which are those likely associated with causing the
and trustworthy sources, according to MalaCards Database.
2
molecular impact promoted by SARS-CoV-2 infection that might be
linked to selected neuropsychiatric disorders. Thus, host differentially
expressed genes (DEGs) from clinical datasets were obtained from pub-
lished data (Blanco-Melo et al., 2020; Ouyang et al., 2020; Xiong et al.,
2020). The selected data were made with clinical samples from
COVID-19 patients. Briefly, Blanco-Melo et al. (2020) used
lung-epithelium derived cells and human bronchial epithelial cells to
identify the differential transcriptional response and protein signature;
Ouyang et al. (2020), identified DEGs from human peripheral blood
mononuclear cells (PBMCs) and the corresponding serum samples; Xiong
et al. (2020) also described the differential transcriptome and tran-
scriptional changes in bronchoalveolar lavage fluid (BALF) and PBMCs
specimens of COVID-19 patients.2.2. Correlation and assignment of DEGs to neuropsychiatric disorders
The described clinical COVID-19 dataset containing host DEGs wasrs that were found differentially expressed in clinical samples from patients with
tially expressed genes (DEGs) identified in these samples, and categorized with
presented in circles (red, upregulated and green, downregulated). Nodes with
disease, since their gene-disease associations are supported by manually curated
A. Quincozes-Santos et al. Brain, Behavior, & Immunity - Health 11 (2021) 100196checked to potential assignment to genes associated with selected
neuropsychiatric disorders found in the MalaCards Human Disease
Database (https://www.malacards.org) (Rappaport et al., 2017), as
previously described (Beys-da-Silva et al., 2020, 2019). The assignment
checking was made manually for each DEG against all genes associated
with the selected neuropsychiatric disorders in MalaCards Database.
3. Results
First, we constructed a database containing DEGs identified in clinical
samples from COVID-19 patients, and this database was then further
checked for potential associations with specific neuropsychiatric disor-
ders. A substantial set of DEGs was found for genes are associated with
alcohol dependence, autism, bipolar disorder, depression, panic disorder,
schizophrenia, and sleep disorder (Fig. 1). According to several publi-
cations, these disorders have been significantly influenced by the COVID-
19 outbreak (Eshraghi et al., 2020; Troyer et al., 2020; Yao et al., 2020).
In addition to the identification of 171 genes linked to these neuropsy-
chiatric disorders (Table S1), it should be highlighted that 12 genes are
associated with causing some of these disorders. These genes, known as
elite genes, according to the MalaCards Database (Rappaport et al.,
2017), are: ADH1B (alcohol dehydrogenase 1B (class I), beta poly-
peptide), ADH1C (alcohol dehydrogenase 1C (class I), gamma poly-
peptide), AKT1 (AKT serine/threonine kinase 1), APOL2 (apolipoprotein
L2), APOL4 (apolipoprotein L4), CHI3L1 (chitinase 3 like 1), EHMT1
(euchromatic histone lysine methyltransferase 1), FKBP5 (FKBP prolyl
isomerase 5), MTHFR (methylenetetrahydrofolate reductase), PTEN
(phosphatase and tensin homolog), SETD1A (SET domain containing 1A,
histone lysine methyltransferase), and SYN2 (synapsin II).
The pathophysiologies of alcohol dependence, autism, bipolar disor-
der, depression, panic disorder, schizophrenia and sleep disorder remain
unclear, but they share a common event: neuroinflammation. In this
regard, we showed that inflammatory markers, such as TNF (tumor ne-
crosis factor), TNFRSF1A and TNFRSF1B (TNF receptor superfamily
member 1A and 1B), IFNG (interferon gamma), IL1B (interleukin 1 beta),
IL1RN (interleukin 1 receptor antagonist), IL10 (interleukin 10), CXCL8
(C-X-C motif chemokine ligand 8), CD38 (CD38 molecule) and PTGS2/
COX2 (prostaglandin-endoperoxide synthase 2/cyclooxygenase 2),
among others, were found to be differentially expressed after SARS-CoV-
2 infection (Fig. 1).
With regard to the elite genes for autism, we identified six genes,
including PTEN, which is part of a signaling pathway implicated in
neuronal survival, synaptic plasticity, learning, and memory (Busch
et al., 2019). In addition, alterations in the expression of other genes
associated with autism were observed, including AKT1, EHMT1, FKBP5,
MTHFR and SYN2. Nine elite genes were identified for schizophrenia,
and some of these are shared with autism, such as AKT1, EHMT1, FKBP5,
MTHFR and SYN2. We identified other DEGs correlated to schizophrenia,
such as APOL2, APOL4, SETD1A, and CHI3L1. With regard to depression
three elite genes have been identified: AKT1, FKBP5 and MTHFR, which
were previously identified for autism and schizophrenia. These genes
regulate key points in the pathogenesis of depression (Park et al., 2019;
Wan et al., 2018). Moreover, we identified other molecular markers that
are significantly associated with depressive disorder (Fig. 1 and
Table S2).
The molecular markers found also indicate significant changes linked
to bipolar disorder, such as the downregulation of ABCB1 (ATP binding
cassette subfamily B member 1), involved in multidrug resistance, and
SLC6A4 (solute carrier family 6 member 4), which controls the transport
of serotonin (Zhu et al., 2017). Moreover, we found two elite genes
associated with alcohol dependence, ADH1B and ADH1C, which play a
major role in ethanol metabolism. IL1RNwas also found upregulated and
may be linked with this condition, as it is associated with inflamma-
tion/genetic predisposition to high alcohol consumption (Blednov et al.,
2015; Tilg et al., 2016).
Several genes that promote significant effects on neurons and glial3
cells were also identified, as up and downregulated, such as NFIB (nu-
clear factor I B), the transcriptional activator of the astrocytic marker
GFAP (glial fibrillary acidic protein), and SLC1A3/EAAT1 (solute carrier
family 1 member 3/excitatory amino acid transporter). Other DEGs were
associated with signal transduction, transcription factors and the cell
cycle, as well as proteins that regulate the oxidative response,
cytoarchitecture and plasticity of the brain; all of these genes remarkably
compromise brain functionality.
4. Discussion
Recent publications indicate that SARS-CoV-2 can cause neurological
complications; however, the majority of studies are limited to epidemi-
ological data observed in the hospitals. The impact of microbial infection
on host’s gene expression is well known to trigger molecular alterations
linked to pathological outcomes. Therefore, considering that clinical
outcomes after COVID-19 are unknown and that their consequences are
potentially dramatic, we surveyed DEGs identified in clinical samples
from COVID-19 patients for a potential correlation with neuropsychiatric
disorders. The early identification of potential susceptible groups with
increased risk of mental health deterioration after SARS-CoV-2 infection
is a matter of global public health interest due to the pandemic status of
COVID-19. Accordingly, the list of molecular markers and diseases pre-
sented here might be useful for this purpose (Table S2). To the best of our
knowledge, this is the first study linking SARS-CoV-2 with specific mo-
lecular markers associated with potential neuropsychiatric sequelae.
Although the neurotropism of SARS-CoV-2 remains unclear, many
studies have shown neurological consequences derived from excessive
inflammatory responses (Li et al., 2020; Zubair et al., 2020). In line with
this, we identified changes in molecular markers associated with neu-
roinflammation. Pro-inflammatory and anti-inflammatory cytokines
were upregulated in clinical samples of COVID-19 patients and these
findings may indicate that SARS-CoV-2 can trigger an excessive inflam-
matory response. It is important to note that central and periphery in-
flammatory mediators, including components of cytokine storm,
interleukin 6 (IL6) and C-reactive protein, are key elements in the
pathomechanisms of several neuropsychiatric disorders, such as
depression and bipolar disorder (Fries et al., 2019; K€ohler-Forsberg et al.,
2017). Thus, COVID-19 patients may present accelerated neuro-
progression and/or psychiatric sequelae associated with inflammation.
De Felice et al. emphasized the importance of determining SARS-CoV-
2 viral load in cerebrospinal fluid, since neurological complications can
be primary or secondary consequences of infection (De Felice et al.,
2020). Independently, several genes that directly affect neurotransmis-
sion and synaptic plasticity have been reported as modulated in clinical
samples of COVID-19 patients, suggesting that SARS-CoV-2 may have the
ability to disturb key neurotransmitter systems, which represent a com-
mon point and a potential trigger for neuropsychiatric disorders.
Notably, the potential neuroinvasion of SARS-CoV-2 can be associated
with an inflammatory response-induced BBB breakdown (Alam et al.,
2020; Yachou et al., 2020; Zubair et al., 2020). In line with this, astro-
cytes form (and reform) the BBB (Vainchtein and Molofsky, 2020), and
we verified an upregulation of a modulator of GFAP, an astrocyte marker.
Accordingly, plasma levels of GFAP have been shown to be increased in
patients with severe and moderate COVID-19 (Kanberg et al., 2020).
As a peculiarity of depression, patients with the other neuropsychi-
atric disorders discussed in this study can also have depression. Depres-
sion should be highlighted, due to its high prevalence in the population
and its association with other chronic pathological conditions. In addi-
tion, depression has been associated with social isolation and all other
psychosocial aspects of the pandemic (Dubey et al., 2020). Moreover,
attention should be paid to subjects with bipolar disorder that are
COVID-19 positive to avoid the aggravation of clinical manifestations
related to this mood disorder, since patients can become depressed and
the mood swings can affect sleep (Volkert et al., 2015). Additionally,
alterations in the expression of genes linked to panic and sleep disorders
A. Quincozes-Santos et al. Brain, Behavior, & Immunity - Health 11 (2021) 100196were observed.
In summary, we observed a remarkable number of molecular markers
associated with neuropsychiatric disorders with altered expression in
clinical samples from COVID-19 patients. Herein, we present a list con-
taining 171 molecular markers that potentially need to be further sur-
veyed in patients with COVID-19 or those recovered from COVID-19.
This clinical follow-up might be particularly important in those patients
previously diagnosed with alcohol dependence, autism, bipolar disorder,
depression, panic disorder, schizophrenia and sleep disorder. These
groups may require special attention from healthcare professionals
because their pre-existing neuropsychiatric conditions might deteriorate
after COVID-19, due to these molecular alterations. Four points are
critical: i) all neuropsychiatric disorders addressed are associated with
inflammatory processes and COVID-19 triggers a cytokine storm; ii)
changes in the expression of genes associated with these disorders,
especially elite genes, can accelerate neurochemical dysfunctions,
aggravating neurological damage in these groups; iii) psychosocial ef-
fects associated with all aspects of the pandemic, such as social distancing
and quarantine, economic burden, mass hysteria, and financial losses
might also aggravate or help to trigger these disorders; and iv) after
COVID-19 recovery, patients may need different management and
pharmacological support to avoid or reduce associated neurological
sequelae.
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